Early Results of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy

"At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months. The rates of patients achieving BCR-ABL1 transcript levels 􏰀 10% and 􏰀 1% at 3 months by the International Standard were 93% and 72%, respec- tively. The rates of complete cytogenetic response by conventional cytogenetics or fluorescence in situ hybridization at 6 and 12 months were 86% and 88%, respectively. At 12 months, 79%, 71%, and 46% of the patients had achieved a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction, respectively. Nine patients had a dose interruption for 􏰀14 days. Only 1 patient developed a pleural effusion requiring a dose reduction to 20 mg. All patients remained alive and with no transformation so far..........."

Kiran Naqvi, MD ; Elias Jabbour, MD ; Jeffrey Skinner, MHA; Musa Yilmaz, MD; Alessandra Ferrajoli, MD; Prithviraj Bose, MD; Philip Thompson, MD; Yesid Alvarado, MD; Nitin Jain, MD; Koichi Takahashi, MD, PhD; Jan Burger, MD, PhD; Zeev Estrov, MD; Gautam Borthakur, MD; Naveen Pemmaraju, MD; Shilpa Paul, PharmD;
Jorge Cortes, MD; and Hagop M. Kantarjian, MD

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31357